Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0PQQJW
|
|||||
---|---|---|---|---|---|---|
ADC Name |
GPC-1 ADC 1
|
|||||
Synonyms |
GPC-1-ADC-1
Click to Show/Hide
|
|||||
Drug Status |
Investigative
|
|||||
Indication |
In total 3 Indication(s)
Adenocarcinoma [ICD11:2D40]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
Squamous cell cancer [ICD11:2D60-2D61]
Investigative
|
|||||
Drug-to-Antibody Ratio |
4.1
|
|||||
Antibody Name |
Anti-GPC1 mAb 01a033
|
Antibody Info | ||||
Antigen Name |
Glypican-1 (GPC1)
|
Antigen Info | ||||
Payload Name |
Monomethyl auristatin F
|
Payload Info | ||||
Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
Combination Type |
VcMMAF
|
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 21.71% (Day 24) | Positive GPC1 expression (GPC1 +++/++) | ||
Method Description |
Antitumor efficacy of GPC1-ADC in HeLa (n = 6/group) xenograft models. When the mean tumor size of each cancer type reached approximately 130 mm3 , PBS, control-ADC or GPC1-ADC (1 mg/kg) was intravenously injected every four days for a total of 4 times.
|
||||
In Vivo Model | HeLa CDX model | ||||
In Vitro Model | Endocervical adenocarcinoma | HeLa cells | CVCL_0030 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 28.13% (Day 32) | Positive GPC1 expression (GPC1 +++/++) | ||
Method Description |
Antitumor efficacy of GPC1-ADC in ME180 (n = 7/group) xenograft models. When the mean tumor size of each cancer type reached approximately 130 mm3 , PBS, control-ADC or GPC1-ADC (1 mg/kg) was intravenously injected every four days for a total of 4 times.
|
||||
In Vivo Model | ME180 CDX model | ||||
In Vitro Model | Cervical squamous cell carcinoma | ME-180 cells | CVCL_1401 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 33.65% (Day 32) | Positive GPC1 expression (GPC1 +++/++) | ||
Method Description |
Antitumor efficacy of GPC1-ADC in ME180 (n = 7/group) xenograft models. When the mean tumor size of each cancer type reached approximately 130 mm3 , PBS, control-ADC or GPC1-ADC (3 mg/kg) was intravenously injected every four days for a total of 4 times.
|
||||
In Vivo Model | ME180 CDX model | ||||
In Vitro Model | Cervical squamous cell carcinoma | ME-180 cells | CVCL_1401 | ||
Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 43.94% (Day 24) | Positive GPC1 expression (GPC1 +++/++) | ||
Method Description |
Antitumor efficacy of GPC1-ADC in HeLa (n = 6/group) xenograft models. When the mean tumor size of each cancer type reached approximately 130 mm3 , PBS, control-ADC or GPC1-ADC (3 mg/kg) was intravenously injected every four days for a total of 4 times.
|
||||
In Vivo Model | HeLa CDX model | ||||
In Vitro Model | Endocervical adenocarcinoma | HeLa cells | CVCL_0030 | ||
Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 69.65% (Day 24) | Positive GPC1 expression (GPC1 +++/++) | ||
Method Description |
Antitumor efficacy of GPC1-ADC in HeLa (n = 6/group) xenograft models. When the mean tumor size of each cancer type reached approximately 130 mm3 , PBS, control-ADC or GPC1-ADC (10 mg/kg) was intravenously injected every four days for a total of 4 times.
|
||||
In Vivo Model | HeLa CDX model | ||||
In Vitro Model | Endocervical adenocarcinoma | HeLa cells | CVCL_0030 | ||
Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.49% (Day 32) | Positive GPC1 expression (GPC1 +++/++) | ||
Method Description |
Antitumor efficacy of GPC1-ADC in ME180 (n = 7/group) xenograft models. When the mean tumor size of each cancer type reached approximately 130 mm3 , PBS, control-ADC or GPC1-ADC (10 mg/kg) was intravenously injected every four days for a total of 4 times.
|
||||
In Vivo Model | ME180 CDX model | ||||
In Vitro Model | Cervical squamous cell carcinoma | ME-180 cells | CVCL_1401 |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.04 nM | Positive GPC1 expression (GPC1 +++/++) | ||
Method Description |
HeLa, ME180, and RMG-1 cells were treated with anti-GPC1 monoclonal antibody (clone 01a033) or control IgG antibody for 144 h.
|
||||
In Vitro Model | Endocervical adenocarcinoma | HeLa cells | CVCL_0030 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.09 nM | Positive GPC1 expression (GPC1 +++/++) | ||
Method Description |
HeLa, ME180, and RMG-1 cells were treated with anti-GPC1 monoclonal antibody (clone 01a033) or control IgG antibody for 144 h.
|
||||
In Vitro Model | Cervical squamous cell carcinoma | ME-180 cells | CVCL_1401 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 100 nM | Negative GPC1 expression (GPC1 -) | ||
Method Description |
HeLa, ME180, and RMG-1 cells were treated with anti-GPC1 monoclonal antibody (clone 01a033) or control IgG antibody for 144 h.
|
||||
In Vitro Model | Ovarian clear cell adenocarcinoma | RMG-I cells | CVCL_1662 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.